Last10K.com

Alexion Pharmaceuticals, Inc. (ALXN) SEC Filing 10-Q Quarterly report for the period ending Sunday, September 30, 2018

SEC Filings

Alexion Pharmaceuticals, Inc.

CIK: 899866 Ticker: ALXN




a2016earningsreleaseimagea12.jpg
Alexion Reports Third Quarter 2018 Results

3Q18 total revenues of $1,026.5 million, a 20 percent increase over 3Q17 and a 26 percent volume increase

3Q18 GAAP diluted EPS of $1.47 per share; non-GAAP diluted EPS of $2.02 per share

Updated 2018 full-year guidance given the strength of the business

Positive topline Phase 3 data for eculizumab in patients with neuromyelitis optica spectrum disorder (NMOSD); regulatory submissions planned for early 2019

Announced agreement to acquire Syntimmune and collaboration with Dicerna

BOSTON, October 24, 2018- Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the third quarter of 2018. Total revenues in the third quarter were $1,026.5 million, a 20 percent increase compared to the same period in 2017. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $8.9 million, inclusive of hedging activities. On a GAAP basis, diluted earnings per share (EPS) in the quarter was $1.47 per share. The third quarter of 2018 included $18.2 million of restructuring and related expenses compared to $164.7 million in the third quarter of 2017. Non-GAAP diluted EPS for the third quarter of 2018 was $2.02 per share, a 40 percent increase versus the third quarter of 2017.

"We continued to execute on our key objectives this quarter, further strengthening our core business and again delivering strong top and bottom-line growth," said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. "Following the groundbreaking Phase 3 results of eculizumab in NMOSD, we are moving quickly to prepare global regulatory submissions, which could make it the first approved therapy for patients with this devastating disease. Our teams continue to demonstrate launch excellence with sustained growth of Soliris® in gMG. In addition, we made significant progress diversifying our portfolio with the anticipated acquisition of Syntimmune and our collaboration with Dicerna. We continue to look for additional opportunities while advancing internal programs to position us for further long-term growth."

Third Quarter 2018 Financial Highlights

Total net product sales were $1,026.5 million in the third quarter of 2018, compared to $1,044.7 million in the second quarter of 2018. Second quarter revenue benefited from favorable timing of orders from certain non-U.S. markets that access Alexion medicines through a tender process as well as approximately $18.2 million related to order timing ahead of the July 4th holiday in the United States, compared to the third quarter of 2018.

Soliris® (eculizumab) net product sales were $888.0 million, compared to $755.4 million in the third quarter of 2017, representing an 18 percent increase. Soliris® volume increased 24 percent year-over-year.


1

The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Wednesday, October 24, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Alexion Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Alexion Pharmaceuticals, Inc..

Continue

Assess how Alexion Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Alexion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
M & A
Legal
Other
Filter Subcategory:
All
Cash Flow
Expense
Product
Shares
Income
Geography
Other
Inside Alexion Pharmaceuticals, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information Document
Restructuring And Related Expenses (Schedule Of Restructuring And Related Costs) (Details)
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income (Parenthetical)
Condensed Consolidated Statements Of Comprehensive Income Statement
Condensed Consolidated Statements Of Operations
(Restructuring Reserve Roll Forward) (Details)
Acquisitions
Acquisitions (Narrative) (Details)
Acquisitions (Summary Of Total Consideration) (Details)
Acquisitions (Tables)
Basis Of Presentation And Principles Of Consolidation
Basis Of Presentation And Principles Of Consolidation Basis Of Presentation And Principles Of Consolidation (Details)
Business
Commitments And Contingencies
Commitments And Contingencies (Narrative) (Details)
Debt
Debt (Details)
Defined Benefit Plans
Derivative Instruments And Hedging Activities
Derivative Instruments And Hedging Activities (Narrative) (Details)
Derivative Instruments And Hedging Activities (Offsetting Assets And Liabilities) (Details)
Derivative Instruments And Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details)
Derivative Instruments And Hedging Activities (Schedule Of Interest Rate Contracts) (Details)
Derivative Instruments And Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details)
Derivative Instruments And Hedging Activities (Tables)
Earnings Per Common Share
Earnings Per Common Share (Narrative) (Details)
Earnings Per Common Share (Summary Of Calculation Of Basic And Diluted Earnings Per Share) (Details)
Earnings Per Common Share (Tables)
Facility Lease Obligations
Facility Lease Obligations (Details)
Fair Value Measurement
Fair Value Measurement (Narrative) (Details)
Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details)
Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details)
Fair Value Measurement (Tables)
Income Taxes
Income Taxes (Narrative) (Details)
Income Taxes (Schedule Of Income Tax Provision And Effective Tax Rate) (Details)
Income Taxes (Tables)
Intangible Assets And Goodwill
Intangible Assets And Goodwill (Narrative) (Details)
Intangible Assets And Goodwill (Schedule Of Intangible Assets And Goodwill) (Details)
Intangible Assets And Goodwill (Tables)
Inventories
Inventories (Details)
Inventories (Tables)
Marketable Securities
Marketable Securities (Available-For-Sale Debt Securities By Contractual Maturity) (Details)
Marketable Securities (Available-For-Sale Investments By Classification In Balance Sheet) (Details)
Marketable Securities (Narrative) (Details)
Marketable Securities (Summary Of Securities Held) (Details)
Marketable Securities (Tables)
Other Comprehensive Income And Accumulated Other Comprehensive Income
Other Comprehensive Income And Accumulated Other Comprehensive Income (Changes In Aoci) (Details)
Other Comprehensive Income And Accumulated Other Comprehensive Income (Significant Reclassifications From Aoci) (Details)
Other Comprehensive Income And Accumulated Other Comprehensive Income (Tables)
Other Investments
Other Investments (Details)
Restructuring And Related Expenses
Restructuring And Related Expenses (Narrative) (Details)
Restructuring And Related Expenses (Tables)
Revenue Recognition
Revenue Recognition (Disaggregation Of Revenue By Product And Geographical Region) (Details)
Revenue Recognition (Narrative) (Details)
Revenue Recognition (Summary Of Receivables And Contract Liabilities From Contracts) (Details)
Revenue Recognition (Tables)
Stockholders' Equity
Stockholders' Equity (Details)
Subsequent Event
Subsequent Event (Details)
Ticker: ALXN
CIK: 899866
Form Type: 10-Q Quarterly Report
Accession Number: 0000899866-18-000131
Submitted to the SEC: Wed Oct 24 2018 4:27:34 PM EST
Accepted by the SEC: Wed Oct 24 2018
Period: Sunday, September 30, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/alxn/0000899866-18-000131.htm